Tags : Non-Oncology Therapeutics

Roche Signs a Technology License Agreement with Amunix Pharmaceutical to

Shots: Amunix to receive $40M up front, up to $1.5B as development & commercial milestones along with royalties on sales of products. Roche to leverage Amunix’s XTEN technology platform to develop novel non-oncology therapies for undisclosed targets The agreement follows Amunix’s previous technology assessment with Roche which focused on utilizing XTEN to extend the half-life […]Read More